A Case of Metastatic Malignant Melanoma Treated with Pembrolizumab
- 1 January 2019
- journal article
- Published by Hans Publishers in Asian Case Reports in Oncology
- Vol. 08 (03), 23-27
- https://doi.org/10.12677/acrpo.2019.83004
Abstract
Immune targeted therapy of malignant tumor is a major progress of clinical oncology in recent years. Programmed cell death receptor (programmed death receptor 1, PD-1)/apoptosis ligand (programmed death ligand 1, PD-L1) signaling pathway blockers treatment of malignant melanoma achieved good results. We applied in China’s newly listed PD-1 inhibitor pembrolizumab in the treatment of a patient with metastatic malignant melanoma pulmonary metastasis, and achieved good result, as reported below.Keywords
This publication has 3 references indexed in Scilit:
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational BurdenThe New England Journal of Medicine, 2018
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2015
- Cancer ImmunotherapyScience, 2013